<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7432271\results\search\drug\results.xml">
  <result pre="date, therapies with proven benefit in certain groups include remdesivir," exact="dexamethasone" post="and convalescent plasma [3,4,5]. This review describes the structure"/>
  <result pre="in the Nidovirales order. The subgroups of the family are" exact="alpha" post="(Î±), beta (Î²), gamma (Î³) and delta (Î´) coronaviruses"/>
  <result pre="a promising candidate for treatment of COVID19. RDV is an" exact="adenosine" post="nucleotide analogue with broad-spectrum antiviral activity against RNA viruses"/>
  <result pre="[107,108] by inhibiting viral proteases including 3CLpro or PLpro [108]." exact="Ritonavir" post="is used in combination with Lopinavir to increase LPV"/>
  <result pre="performance and safety of favipiravir in combination with oseltamivir and" exact="chloroquine" post="among 80 participants with COVID-19 in Rajavithi Hospital in"/>
  <result pre="however caution is required as it is teratogenic [119]. 8.1.4." exact="Ribavirin" post="Ribavirin (1-Î²-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a synthetic guanosine analogue with broad-spectrum"/>
  <result pre="caution is required as it is teratogenic [119]. 8.1.4. Ribavirin" exact="Ribavirin" post="(1-Î²-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a synthetic guanosine analogue with broad-spectrum activity"/>
  <result pre="B and in combination with interferon-Î± for hepatitis C [126]." exact="Ribavirin" post="has multiple mechanisms of action-including interference with RNA capping,"/>
  <result pre="response [127]. The in vitro anti SARS-CoV activity reported for" exact="ribavirin" post="differs widely depending on the cell lines used for"/>
  <result pre="lines used for the antiviral assays. It is possible that" exact="ribavirin" post="may be more effective when co-administrated with IFN as"/>
  <result pre="single treatment alone [128]. Similarly, the combination of IFN-Î±2b and" exact="ribavirin" post="in vitro decreased the inhibitory concentration against MERS-CoV to"/>
  <result pre="of SARS-CoV-2, in vitro studies revealed that high concentrations of" exact="ribavirin" post="(EC50 of 109.5 ÂµM) are required to reduce the"/>
  <result pre="109.5 ÂµM) are required to reduce the viral infection and" exact="ribavirin" post="is 100 times less potent than remdesivir [101]. Administration"/>
  <result pre="less potent than remdesivir [101]. Administration of high doses of" exact="ribavirin" post="in SARS trials was associated with serious adverse reactions"/>
  <result pre="data evaluating the efficacy of this compound, the administration of" exact="ribavirin" post="for the treatment of COVID-19 is not recommended. An"/>
  <result pre="in China (ChiCTR2000029387) is evaluating the efficacy and safety of" exact="ribavirin" post="and LPV/r in combination with interferon alpha-1b for SARS-CoV-2"/>
  <result pre="demonstrated that serine proteases cause the spread of SARS-CoV and" exact="camostat" post="effectively prevents this step, suggesting it may be an"/>
  <result pre="treating SARS and potentially MERS [141]. Another study demonstrated that" exact="camostat" post="partially blocked SARS-CoV and human coronavirus NL63 (HCoV-NL63) infection"/>
  <result pre="the ACE2 receptor and TMPRSS2 [142]. Additionally, the effect of" exact="camostat" post="mesylate in blocking SARS-CoV-2 infection of human lung Calu-3"/>
  <result pre="double-blind randomized controlled clinical trial is evaluating the efficacy of" exact="camostat" post="mesylate for treatment of COVID-19 (NCT04353284), but more studies"/>
  <result pre="the virus can be attained in a patientâ€™s lung. 8.1.7." exact="Nafamostat" post="Mesylate Nafamostat mesylate (6-amidino-2-naphthyl p guanidinobenzoate dimethanesulfonate) is a"/>
  <result pre="can be attained in a patientâ€™s lung. 8.1.7. Nafamostat Mesylate" exact="Nafamostat" post="mesylate (6-amidino-2-naphthyl p guanidinobenzoate dimethanesulfonate) is a synthetic serine"/>
  <result pre="for the treatment of inflammatory-related diseases such as pancreatitis [144,145]." exact="Nafamostat" post="is a potent inhibitor of S-mediated membrane fusion of"/>
  <result pre="MERS-CoV infection in vitro [22]. The anti MERS-CoV activity of" exact="nafamostat" post="is through inhibition of the host protease TMPRSS2, which"/>
  <result pre="study in lung cell culture tested the inhibitory effect of" exact="gabexate" post="mesylate, nafamostat mesylate and camostat mesylate on SARS-CoV-2 infection"/>
  <result pre="lung cell culture tested the inhibitory effect of gabexate mesylate," exact="nafamostat" post="mesylate and camostat mesylate on SARS-CoV-2 infection and demonstrated"/>
  <result pre="tested the inhibitory effect of gabexate mesylate, nafamostat mesylate and" exact="camostat" post="mesylate on SARS-CoV-2 infection and demonstrated that nafamostat mesylate"/>
  <result pre="mesylate and camostat mesylate on SARS-CoV-2 infection and demonstrated that" exact="nafamostat" post="mesylate inhibited S-mediated entry of SARS-CoV-2 into host cells"/>
  <result pre="of SARS-CoV-2 into host cells 15 times more effectively that" exact="camostat" post="mesylate, with an EC50 in the low nanomolar range"/>
  <result pre="EC50 in the low nanomolar range [146]. In another study," exact="nafamostat" post="was tested in vitro against a clinical SARS-CoV-2 isolate"/>
  <result pre="target. Despite these promising in vitro data, the efficacy of" exact="nafamostat" post="as a COVID-19 treatment needs to be tested in"/>
  <result pre="to be tested in clinical trials. 8.2. Anti-Parasites 8.2.1. Chloroquine/Hydroxychloroquine" exact="Chloroquine" post="(N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine) has long been used to prevent and treat"/>
  <result pre="and herpes simplex virus [147]. Sometimes the antiviral activities of" exact="chloroquine" post="described in vitro have been confirmed in virus-infected patients,"/>
  <result pre="the results have not always been reproduced in clinical trials." exact="Chloroquine" post="possesses different mechanisms of action depending on the pathogen"/>
  <result pre="the pathogen studied. In vitro studies on SARS-CoV showed that" exact="chloroquine" post="can interfere with glycosylation of ACE2, in Vero cells"/>
  <result pre="Since SARS-CoV-2 uses a similar receptor, it is expected that" exact="chloroquine" post="may prevent SARS-CoV-2 attachment to target cells by the"/>
  <result pre="SARS-CoV-2 attachment to target cells by the same mechanism. Moreover," exact="chloroquine" post="can induce autophagosome formation resulting in spike protein degradation"/>
  <result pre="changing the pH of lysosomes and inhibition of cathepsins. Furthermore," exact="chloroquine" post="interferes with viral assembly, budding and proteolytic processing of"/>
  <result pre="(MAPK) [149]. Previous studies have reported the potential use of" exact="chloroquine" post="for treatment of SARS-CoV [150]. The potent efficacy of"/>
  <result pre="treatment of SARS-CoV [150]. The potent efficacy of remdesivir and" exact="chloroquine" post="were evaluated in Vero E6; chloroquine was effective in"/>
  <result pre="efficacy of remdesivir and chloroquine were evaluated in Vero E6;" exact="chloroquine" post="was effective in controlling SARS-CoV-2 infection in vitro with"/>
  <result pre="the lung [101]. There is safety concern in administration of" exact="chloroquine" post="due to the risk of macular retinopathy and cardiomyopathy"/>
  <result pre="in vitro efficiency of chloroquine, the clinical outcomes are uncertain." exact="Hydroxychloroquine" post="sulfate, a derivative form of chloroquine, was first synthesized"/>
  <result pre="two to three times less toxicity in animals compared to" exact="chloroquine" post="[154]. Hydroxychloroquine likely has the same mechanism of action"/>
  <result pre="three times less toxicity in animals compared to chloroquine [154]." exact="Hydroxychloroquine" post="likely has the same mechanism of action on viruses"/>
  <result pre="the same mechanism of action on viruses as that of" exact="chloroquine" post="and acts as a weak base compound, changing the"/>
  <result pre="[155]. There is limited published evidence supporting the activity of" exact="hydroxychloroquine" post="against coronaviruses. An in vitro study in Vero cells"/>
  <result pre="An in vitro study in Vero cells showed that the" exact="chloroquine" post="was approximately 5-fold more potent (EC50 of 6.5 Â±"/>
  <result pre="potent (EC50 of 6.5 Â± 3.2 Î¼M) than that of" exact="hydroxychloroquine" post="(EC50 of 34 Â± 5 Î¼M) against SARS-CoV [156]."/>
  <result pre="Â± 5 Î¼M) against SARS-CoV [156]. Conversely, the potency of" exact="hydroxychloroquine" post="in Vero cells infected with SARS-CoV-2 (EC50 of 0.72"/>
  <result pre="SARS-CoV-2 (EC50 of 0.72 Î¼M) was greater than that of" exact="chloroquine" post="(EC50 of 5.47 Î¼M) [157]. In a non-randomized open-label"/>
  <result pre="[157]. In a non-randomized open-label trial in France, administration of" exact="hydroxychloroquine" post="significantly reduced the viral load in COVID-19 patients, alone"/>
  <result pre="as well as enrolment of asymptomatic individuals. Widespread administration of" exact="hydroxychloroquine" post="is likely to cause rare adverse effects in patients,"/>
  <result pre="with azithromycin) [159]. It has been shown the combination of" exact="hydroxychloroquine" post="and azithromycin in COVID-19 patients is associated with increased"/>
  <result pre="[159]. It has been shown the combination of hydroxychloroquine and" exact="azithromycin" post="in COVID-19 patients is associated with increased risk of"/>
  <result pre="the FDA does not recommend combination therapy of remdesivir with" exact="chloroquine" post="phosphate or hydroxychloroquine sulfate as it might result in"/>
  <result pre="not recommend combination therapy of remdesivir with chloroquine phosphate or" exact="hydroxychloroquine" post="sulfate as it might result in a reduced antiviral"/>
  <result pre="of remdesivir [162]. Moreover, the FDA announced the use of" exact="hydroxychloroquine" post="and chloroquine for treatment of hospitalized COVID-19 patients can"/>
  <result pre="[162]. Moreover, the FDA announced the use of hydroxychloroquine and" exact="chloroquine" post="for treatment of hospitalized COVID-19 patients can cause serious"/>
  <result pre="withdrew the emergency use authorization it issued in March for" exact="chloroquine" post="and hydroxychloroquine as COVID-19 treatments. The FDA made this"/>
  <result pre="emergency use authorization it issued in March for chloroquine and" exact="hydroxychloroquine" post="as COVID-19 treatments. The FDA made this determination based"/>
  <result pre="the Chinese clinical trial registry (http://www.chictr.org.cn) testing the efficacy of" exact="chloroquine" post="and hydroxychloroquine. In addition, hydroxychloroquine is now under evaluation"/>
  <result pre="(http://www.chictr.org.cn) testing the efficacy of chloroquine and hydroxychloroquine. In addition," exact="hydroxychloroquine" post="is now under evaluation in the U.S. (NCT04308668) as"/>
  <result pre="guidelines panel for COVID-19 treatment recommended against the use of" exact="chloroquine" post="or hydroxychloroquine for the treatment of COVID-19, except in"/>
  <result pre="for COVID-19 treatment recommended against the use of chloroquine or" exact="hydroxychloroquine" post="for the treatment of COVID-19, except in a clinical"/>
  <result pre="trial. The panel also recommends against the use of high-dose" exact="chloroquine" post="(600 mg twice daily for 10 days) for the"/>
  <result pre="on Vero-hSLAM cell lines infected with SARS-CoV-2 has shown that" exact="ivermectin" post="can reduce viral RNA up to 5000-fold, equal to"/>
  <result pre="h [166]. Momekov et al. using available pharmacokinetic data from" exact="ivermectin" post="showed that its inhibitory concentrations against the SARS-CoV-2 is"/>
  <result pre="unlikely attainable in humans [169]. Overall, the possible efficacy of" exact="ivermectin" post="against SARS-CoV-2 infection needs data to support it. 9."/>
  <result pre="virus titer in animal models [215]. 10. Adjunctive/Supportive Therapy 10.1." exact="Azithromycin" post="Azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) is a widely used macrolide antibiotic which"/>
  <result pre="titer in animal models [215]. 10. Adjunctive/Supportive Therapy 10.1. Azithromycin" exact="Azithromycin" post="(9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) is a widely used macrolide antibiotic which can"/>
  <result pre="bacteria by targeting 23S ribosomal RNA. Beside its antibacterial activity," exact="azithromycin" post="has immunomodulatory and anti-viral effects. Previous studies have suggested"/>
  <result pre="anti-viral effects. Previous studies have suggested an antiviral function for" exact="azithromycin" post="in Ebola virus infection, both in vitro and in"/>
  <result pre="Ebola virus infection, both in vitro and in mice [216]." exact="Azithromycin" post="(but not other macrolides like erythromycin or telithromycin) can"/>
  <result pre="and in mice [216]. Azithromycin (but not other macrolides like" exact="erythromycin" post="or telithromycin) can inhibit rhinovirus replication and release in"/>
  <result pre="expression of interferon and pro-inflammatory cytokines (IL-6 and IL-8) [217]." exact="Azithromycin" post="also shows dose dependent antiviral activity against Zika virus"/>
  <result pre="responses [218]. Interestingly, Tran et al. reported antiviral activity of" exact="azithromycin" post="against Influenza (H1N1) virus; treatment prior to infection inhibited"/>
  <result pre="cells, without changing viral attachment [219]. Moreover, intranasal administration of" exact="azithromycin" post="to infected mice reduced the viral load in affected"/>
  <result pre="COVID-19 patients (n = 36), Gautret et al. reported that" exact="azithromycin" post="co-administered with hydroxychloroquine reduced the viral load more efficiently"/>
  <result pre="= 36), Gautret et al. reported that azithromycin co-administered with" exact="hydroxychloroquine" post="reduced the viral load more efficiently than hydroxychloroquine alone"/>
  <result pre="co-administered with hydroxychloroquine reduced the viral load more efficiently than" exact="hydroxychloroquine" post="alone [158]. Patients were administered hydroxychloroquine (600 mg/day), with"/>
  <result pre="load more efficiently than hydroxychloroquine alone [158]. Patients were administered" exact="hydroxychloroquine" post="(600 mg/day), with or without azithromycin (500 mg day"/>
  <result pre="[158]. Patients were administered hydroxychloroquine (600 mg/day), with or without" exact="azithromycin" post="(500 mg day one, followed by 250 mg/day for"/>
  <result pre="combination group (6/6) were virologically cured (negative swab), compared to" exact="hydroxychloroquine" post="alone (57.1%) or untreated controls (12.5%) [158]. However, this"/>
  <result pre="was not randomized, patients were not well matched and adding" exact="azithromycin" post="to hydroxychloroquine may increase the risk of cardiac arrhythmias."/>
  <result pre="randomized, patients were not well matched and adding azithromycin to" exact="hydroxychloroquine" post="may increase the risk of cardiac arrhythmias. There are"/>
  <result pre="are now several larger clinical trials investigating the efficacy of" exact="azithromycin" post="in COVID-19 patients (e.g., NCT04332107, NCT04336332, NCT04329832), but until"/>
  <result pre="(e.g., NCT04332107, NCT04336332, NCT04329832), but until these results are available," exact="Azithromycin" post="cannot be recommended for routine use in COVID-19. 10.2."/>
  <result pre="observational study of SARS-CoV-2 infected patients treated with 40 mg" exact="methylprednisolone" post="once or twice daily, there was no significant association"/>
  <result pre="of hospitalization [226]. Similarly, Fang et al. reported that low-dose" exact="methylprednisolone" post="by injection (median hydrocortisone-equivalent dose, 250 mg/day) or orally"/>
  <result pre="randomized evaluation of COVID-19 therapy (RECOVERY) trial (NCT04381936) found that" exact="dexamethasone" post="(6 milligrams/day for 10 days) can save lives in"/>
  <result pre="benefit, the NIH COVID-19 treatment guidelines panel recommended administration of" exact="dexamethasone" post="(6 mg/day for up to 10 days) for mechanically"/>
  <result pre="hypoglycemia should be considered by the treating clinicians [2]. 10.3." exact="Nitric Oxide" post="Nitric Oxide (NO) is a free radical with vasodilator"/>
  <result pre="be considered by the treating clinicians [2]. 10.3. Nitric Oxide" exact="Nitric Oxide" post="(NO) is a free radical with vasodilator properties. In"/>
  <result pre="[231]. In vitro studies have reported antiviral activity of the" exact="nitric oxide" post="donor compound S-nitroso-N-acetylpenicillamine for inhibition of SARS-Co-V replication in"/>
  <result pre="for inhibition of SARS-Co-V replication in Vero E6 cells [232,233]." exact="Nitric oxide" post="inhalation has also been shown to have long term"/>
  <result pre="after treatment) in ARDS with regard to pulmonary function [234]." exact="Nitric oxide" post="can inhibit both RNA and protein synthesis of SARS-CoV"/>
  <result pre="RNA and protein synthesis of SARS-CoV in vitro [232]. Moreover," exact="nitric oxide" post="or its derivatives can inhibit palmitoylation of the viral"/>
  <result pre="binding to its receptor ACE2 and inhibiting SARS-Co-V replication [235]." exact="Nitric oxide" post="inhalation has been successfully used to treat SARS patients,"/>
  <result pre="are several clinical trials currently investigating the therapeutic potential of" exact="nitric oxide" post="therapy in patients with COVID-19 (NCT04358588, NCT04305457), as more"/>
  <result pre="critically ill COVID-19 patients and the NIH panel recommends using" exact="dexamethasone" post="at proven doses in COVID-19 patients who are mechanically"/>
  <result pre="are not mechanically ventilated [2]. Early data on administration of" exact="hydroxychloroquine" post="often in combination with azithromycin were promising, however studies"/>
  <result pre="Early data on administration of hydroxychloroquine often in combination with" exact="azithromycin" post="were promising, however studies were very low quality, with"/>
  <result pre="from the Solidarity Trialâ€™s International Steering Committee to discontinue the" exact="hydroxychloroquine" post="arm in the trial. The fusion inhibitor umifenovir and"/>
  <result pre="in the trial. The fusion inhibitor umifenovir and protease inhibitor" exact="lopinavir" post="/ritonavir were also regarded initially as likely effective candidates"/>
  <result pre="media. The widespread empiric use of unproven agents such as" exact="hydroxychloroquine" post="can lead to supply shortages for people who rely"/>
  <result pre="programmed death-1 CDC left for disease control and prevention NO" exact="nitric oxide" post="cGMP cyclic guanosine monophosphate GM-CSF granulocyte-monocyte stimulating factor References"/>
  <result pre="coronavirus S1 region and its monoclonal antibodyGenes Genom.20143638739710.1007/s13258-014-0186-9 22.YamamotoM.MatsuyamaS.LiX.TakedaM.KawaguchiY.InoueJ.-I.MatsudaZ.Identification of" exact="Nafamostat" post="as a Potent Inhibitor of Middle East Respiratory Syndrome"/>
  <result pre="inhibits both epidemic and zoonotic coronavirusesSci. Transl. Med.20179eaal365310.1126/scitranslmed.aal365328659436 101.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HÃºZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="1-f8-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamideScience197217770570610.1126/science.177.4050.7054340949 126.ThomasE.GhanyM.G.LiangT.J.The application and mechanism of action of" exact="ribavirin" post="in therapy of hepatitis CAntivir. Chem. Chemother.20122311210.3851/IMP212522592135 127.GraciJ.D.CameronC.E.Mechanisms of"/>
  <result pre="therapy of hepatitis CAntivir. Chem. Chemother.20122311210.3851/IMP212522592135 127.GraciJ.D.CameronC.E.Mechanisms of action of" exact="ribavirin" post="against distinct virusesRev. Med. Virol.200516374810.1002/rmv.483 128.MorgensternB.MichaelisM.BaerP.C.DoerrH.W.CinatlJ.CinatlJ.Ribavirin and interferon-Î² synergistically"/>
  <result pre="ribavirinSci. Rep.20133srep0168610.1038/srep0168623594967 130.KnowlesS.R.PhillipsE.J.DresserL.MatukasL.Common Adverse Events Associated with the Use of" exact="Ribavirin" post="for Severe Acute Respiratory Syndrome in CanadaClin. Infect. Dis.2003371139114210.1086/37830414523782"/>
  <result pre="142.KawaseM.ShiratoK.Van Der HoekL.TaguchiF.MatsuyamaS.Simultaneous Treatment of Human Bronchial Epithelial Cells with" exact="Serine" post="and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome"/>
  <result pre="by a Clinically Proven Protease InhibitorCell202018127128010.1016/j.cell.2020.02.05232142651 144.IwakiM.InoY.MotoyoshiA.OzekiM.SatoT.KurumiM.AoyamaT.Pharmacological studies of FUT-175," exact="nafamostat" post="mesilate. V. Effects on the pancreatic enzymes and experimental"/>
  <result pre="145.ChenX.XuZ.ZengS.WangX.LiuW.QianL.WeiJ.YangX.ShenQ.GongZ.et al.The Molecular Aspect of Antitumor Effects of Protease Inhibitor" exact="Nafamostat" post="Mesylate and Its Role in Potential Clinical ApplicationsFront. Oncol.2019985210.3389/fonc.2019.0085231552177"/>
  <result pre="COVID-19Antimicrob. Agents Chemother.20206410.1128/AAC.00754-20 147.DevauxC.A.RolainJ.-M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: What to expect for COVID-19?Int. J. Antimicrob."/>
  <result pre="inhibitor of SARS coronavirus infection and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 149.SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
  <result pre="other developing countriesDiabetes Metab. Syndr. Clin. Res. Rev.20201424124610.1016/j.dsx.2020.03.01132247211 150.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: An old drug against todayâ€™s diseasesLancet"/>
  <result pre="An old drug against todayâ€™s diseasesLancet Infect. Dis.2003372272710.1016/S1473-3099(03)00806-514592603 151.ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int. J. Antimicrob. Agents20205510593210.1016/j.ijantimicag.2020.10593232145363"/>
  <result pre="J. Antimicrob. Agents20205510593210.1016/j.ijantimicag.2020.10593232145363 152.BernsteinH.N.Ocular safety of hydroxychloroquineAnn. Ophthalmol.1991232922961952638 153.RatliffN.B.EstesM.L.MylesJ.L.ShireyE.K.McMahonJ.T.Diagnosis of" exact="Chloroquine" post="Cardiomyopathy by Endomyocardial BiopsyN. Engl. J. Med.198731619119310.1056/NEJM1987012231604053796692 154.McChesneyE.W.Animal toxicity"/>
  <result pre="Endomyocardial BiopsyN. Engl. J. Med.198731619119310.1056/NEJM1987012231604053796692 154.McChesneyE.W.Animal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfateAm. J. Med.198375111810.1016/0002-9343(83)91265-26408923 155.Al-BariM.A.A.Targeting endosomal acidification by chloroquine analogs"/>
  <result pre="pharmacokinetics of hydroxychloroquine sulfateAm. J. Med.198375111810.1016/0002-9343(83)91265-26408923 155.Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
  <result pre="Vitro Antiviral Activity and Projection of Optimized Dosing Design of" exact="Hydroxychloroquine" post="for the Treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
  <result pre="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 158.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
  <result pre="an open-label non-randomized clinical trialInt. J. Antimicrob. Agents2020202010594910.1016/j.ijantimicag.2020.105949 159.FernerR.E.AronsonJ.K.Chloroquine and" exact="hydroxychloroquine" post="in covid-19BMJ2020369m143210.1136/bmj.m143232269046 160.LiewD.RobertsD.HillC.Hydroxychloroquine for COVID-19: A Cautionary Tale. InSight+Available"/>
  <result pre="15 June 2020) 163.collab: Administration FaDFDA Cautions Against Use of" exact="Hydroxychloroquine" post="or Chloroquine for COVID-19 Outside of the Hospital Setting"/>
  <result pre="2020) 163.collab: Administration FaDFDA Cautions Against Use of Hydroxychloroquine or" exact="Chloroquine" post="for COVID-19 Outside of the Hospital Setting or a"/>
  <result pre="on 1 July 2020) 164.No Clinical Benefit from Use of" exact="Hydroxychloroquine" post="in Hospitalised Patients with COVID-19562020Available online: https://www.ox.ac.uk/news/2020-06-05-no-clinical-benefit-use-hydroxychloroquine-hospitalised-patients-covid-19(accessed on 5"/>
  <result pre="Guidelines1662020Available online: https://www.covid19treatmentguidelines.nih.gov/(accessed on 30 July 2020) 166.CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir. Res.202017810478710.1016/j.antiviral.2020.10478732251768 167.WagstaffK.M.RawlinsonS.M.HearpsA.C.JansD.A.An"/>
  <result pre="Inhibitors of Nuclear ImportJ. Biomol. Screen.20111619220010.1177/108705711039036021297106 168.YangS.N.AtkinsonS.C.WangC.LeeA.BogoyevitchM.A.BorgN.A.JansD.A.The broad spectrum antiviral" exact="ivermectin" post="targets the host nuclear transport importin Î±/Î²1 heterodimerAntivir. Res.202017710476010.1016/j.antiviral.2020.10476032135219"/>
  <result pre="233.KeyaertsE.VijgenL.ChenL.MaesP.HedenstiernaG.Van RanstM.Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a" exact="nitric oxide" post="donor compoundInt. J. Infect. Dis.2004822322610.1016/j.ijid.2004.04.01215234326 234.DellingerR.P.TrzeciakS.CrinerG.ZimmermanJ.L.TaylorR.W.UsanskyH.YoungJ.GoldsteinB.Association between inhaled nitric"/>
  <result pre="nitric oxide donor compoundInt. J. Infect. Dis.2004822322610.1016/j.ijid.2004.04.01215234326 234.DellingerR.P.TrzeciakS.CrinerG.ZimmermanJ.L.TaylorR.W.UsanskyH.YoungJ.GoldsteinB.Association between inhaled" exact="nitric oxide" post="treatment and long-term pulmonary function in survivors of acute"/>
  <result pre="survivors of acute respiratory distress syndromeCrit. Care201216R3610.1186/cc1121522386043 235.Ã…kerstrÃ¶mS.GunalanV.KengC.T.TanY.-J.MirazimiA.Dual effect of" exact="nitric oxide" post="on SARS-CoV replication: Viral RNA production and palmitoylation of"/>
  <result pre="and palmitoylation of the S protein are affectedVirology20093951910.1016/j.virol.2009.09.00719800091 236.ChenL.LiuP.GaoH.SunB.ChaoD.WangF.ZhuY.HedenstiernaG.WangC.G.Inhalation of" exact="Nitric Oxide" post="in the Treatment of Severe Acute Respiratory Syndrome: A"/>
  <result pre="NCT04321616 [237] Lopinavir/Ritonavir Viral protease Anti-viral Oral administration 400 mg" exact="lopinavir" post="and 100 mg ritonavir twice a day for 14"/>
  <result pre="protease Anti-viral Oral administration 400 mg lopinavir and 100 mg" exact="ritonavir" post="twice a day for 14 days, peroral ACTRN12620000445976, NCT02735707,"/>
  <result pre="a day on day 2âˆ’14. 2020-001435-27, NCT04359615, NCT04303299, NCT04402203 [120]" exact="Ribavirin" post="viral RNA Anti-viral 500 mg each time, 2 to"/>
  <result pre="TMPRSS2 Anti-viral 600 mg (200 mg, three times) NCT04353284 [240]" exact="Nafamostat" post="TMPRSS2 Anti-viral 240 mg daily, for 5 days, peroral"/>
  <result pre="Anti-viral 240 mg daily, for 5 days, peroral NCT04418128 [138]" exact="Chloroquine" post="Phosphate ACE2 Anti-parasite 500 mg (300 mg for chloroquine)"/>
  <result pre="chloroquine) each time, 2 times/day NCT04303507, NCT04324463, NCT04353336, NCT04328493 [238]" exact="Hydroxychloroquine" post="Endosome, pH elevation Anti-parasite 200 mg, three times per"/>
  <result pre="for 3 days NCT04343092, NCT04392427 [242] Tocilizumab IL-6 receptor subunit" exact="alpha" post="Monoclonal antibody 400 mg intravenous or 8 mg/kg Ã—"/>
  <result pre="250 mg/day for the next four days (in combination with" exact="hydroxychloroquine" post="NCT04359316, NCT04332107, NCT04336332, NCT04329832 [158] Corticosteroides Binds glucocorticoid receptor"/>
  <result pre="Corticosteroides Binds glucocorticoid receptor and suppress inflammation Anti-Inflammation 40 mg" exact="methylprednisolone" post="once or twice daily NCT04273321 [226] Dexamethasone Binds glucocorticoid"/>
 </snippets>
</snippetsTree>
